

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
1	17/WM/0110	212527	PHITT	28/06/2017	12/10/2017	28/04/2017	29/11/2017	29/11/2017	29/11/2017	30/11/2017	Benchmark Met
2	16/SC/0271	187103	plasmaMATCH	16/06/2017	16/10/2017	21/09/2016	10/11/2017	15/11/2017	24/11/2017	27/11/2017	Benchmark Met
3	16/LO/0680	186642	SMILE (PENTA 17)	10/11/2016	09/11/2017	28/07/2016	21/12/2017	05/01/2018	06/03/2018		Neither
4	17/LO/1656	229212	IMspire 170	18/08/2017	09/11/2017	14/11/2017	22/11/2017	05/12/2017	11/12/2017	12/01/2018	Benchmark Met
5	17/LO/1865	232414	Combination therapy with isatuximab in patients with multiple myeloma	11/04/2017	21/02/2018	13/12/2017	21/03/2018	03/04/2018	20/04/2018	21/06/2018	Neither
6	17/SW/0174	228278	A Phase 2 Clinical Trial in Patients with AML version amend 4	11/09/2017	26/02/2018	20/02/2018	19/01/2018	19/03/2018	06/04/2018		Neither
7	16/NS/0106	212541	RAACENO	11/10/2017	11/10/2017	04/04/2017	19/10/2017	24/11/2017	13/12/2017	21/02/2018	Neither
8	17/LO/0334	214459	FLO-ELA	16/11/2017	24/11/2017	29/03/2017	09/01/2018	08/02/2018	05/03/2018	15/03/2018	Sponsor
9	17/EM/0301	209448	The SANDWICH Trial	04/08/2017	05/12/2017	29/09/2017	14/12/2017	14/12/2017	05/02/2018	06/02/2018	Benchmark Met
10	17/YH/0392	230501	BI 1467335 in patients with diabetic retinopathy.	04/08/2017	13/12/2017	26/01/2017	15/01/2018	23/01/2018	19/02/2018		Sponsor
11	17/LO/1943	233068	Phase III study of inclisiran sodium in subjects with HeFH	09/10/2017	02/01/2018	10/01/2018	24/01/2018	25/01/2018			Sponsor
12	17/EE/0474	229785	AdAPT: Adenovirus after Allogeneic Paediatric Transplantation	24/11/2017	26/01/2018	05/01/2018	19/04/2018	20/04/2018	02/05/2018		Both
13	16/LO/1502	178292	CTC-STOP	25/01/2018	23/04/2018	07/10/2016	05/06/2018	05/06/2018	28/09/2018		Both
14	16/ES/0110	207747	TOPaZ study	13/01/2017	15/05/2018	12/01/2017	15/05/2018	16/05/2018	05/09/2018		Sponsor
15	18/NW/0015	233850	CONSTANT	12/10/2017	20/02/2018	20/02/2018	22/02/2018	22/02/2018	05/03/2018	21/03/2018	Benchmark Met
16	17/SS/0082	222441	SoSTART	08/02/2018	27/02/2018	05/10/2017	27/02/2018	04/04/2018	11/04/2018	23/08/2018	Neither
17	17/EE/0437	233853	AQUILA (54767414SMM3001)	09/08/2017	28/02/2018	10/01/2018	13/04/2018	11/05/2018	11/05/2018	22/05/2018	Neither
18	16/LO/1495	207629	SPACE	05/12/2017	09/03/2018	12/06/2017	09/03/2018	12/03/2018	17/04/2018	05/07/2018	Both
19	17/NE/0238	225047	A Single-dose Pharmacokinetics Study of MK-7655A in Pediatric Subjects	14/07/2017	15/03/2018	05/10/2017	23/05/2018	29/05/2018	21/06/2018		Both
20	16/EE/0446	214004	Niraparib in men with mCRPC and DNA repair anomalies	05/02/2018	16/03/2018	04/01/2017	13/03/2018	16/03/2018	03/05/2018		Neither
21	17/SW/0201	180937	MiBRVO	01/01/2015	08/05/2018	06/04/2018	08/05/2018	11/05/2018	30/05/2018		Neither
22	17/SW/0202	180940	MiCRVO	01/01/2015	08/05/2018	29/01/2018	08/05/2018	11/05/2018	30/05/2018		Neither
23	17/SC/0471	180934	Oral Minocycline for GA	01/01/2015	23/03/2018	13/03/2018	23/04/2018	30/04/2018	02/05/2018	11/05/2018	Benchmark Met
24	18/SC/0055	239091	Be on the TEAM: Teenagers Against Meningitis	18/12/2017	26/03/2018	05/03/2018	28/03/2018	29/03/2018	11/04/2018	13/04/2018	Benchmark Met

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
25	17/SW/0273	235783	SB11-G31-AMD-Comparison of efficacy&safety of SB11 and Lucentis in AMD	21/07/2017	26/03/2018	22/01/2018	15/03/2018	28/03/2018	23/04/2018	02/05/2018	Benchmark Met
26	18/SC/0015	236685	Adjuvant canakinumab vs placebo in stages IB, II-IIIa resected NSCLC	16/02/2018	27/03/2018	23/02/2018	11/04/2018	13/04/2018	27/04/2018	07/06/2018	Neither
27	16/LO/1979	193891	STATEC	19/07/2016	09/01/2018	20/12/2016	16/01/2018	18/01/2018	23/02/2018	07/03/2018	Benchmark Met
28	17/EE/0040	222216	ENCIRCLE Emergency Cerclage in Twins at Imminent Risk of preterm birth	12/01/2018	16/01/2018	02/03/2017	21/02/2018	22/02/2018	26/03/2018		Neither
29	17/LO/0108	221119	MASTER DAPT	01/02/2018	13/02/2018	10/04/2017	27/02/2018	05/04/2018	16/04/2018	16/04/2018	Benchmark Met
30	18/LO/0205	211278	Thermic-3	28/02/2018	16/03/2018	16/03/2018	16/03/2018	04/05/2018	04/05/2018	20/06/2018	Sponsor
31	16/LO/2186	188540	IMAT-Neuroblastoma	27/10/2017	03/05/2018	17/01/2017	03/05/2018	03/05/2018	04/05/2018	14/05/2018	Benchmark Met
32	17/LO/0731	219463	PIVOTALboost	12/09/2017	21/03/2018	27/07/2017	16/04/2018	23/04/2018	13/06/2018		Sponsor
33	17/NW/0529	226070	PPAC2: Packing of Perianal Abscess Cavities 2	01/03/2018	27/03/2018	05/12/2017	05/04/2018	08/05/2018	04/06/2018	20/06/2018	Sponsor
34	17/LO/1472	229826	LN-145 in Advanced Cervical Carcinoma	13/11/2017	19/02/2018	27/10/2017	20/05/2018	31/05/2018	07/06/2018	13/07/2018	NHS Provider
35	17/EM/0468	234972	A3921104 - Tofacitinib for treatment of Juvenile Idiopathic Arthritis	13/09/2017	04/04/2018	27/03/2018	05/04/2018	10/04/2018	26/04/2018		Neither
36	17/YH/0381	225986	GAP Study: Gabapentin in Post Surgery Pain	17/01/2018	04/04/2018	09/01/2018	05/04/2018	05/04/2018	12/04/2018	24/04/2018	Benchmark Met
37	17/LO/0933	220629	SAPPHIRE - A randomised study for participants with RVO	01/06/2017	09/04/2018	15/01/2018	23/03/2018	11/04/2018			Sponsor
38	16/SC/0526	208162	EYS606-CT1	07/09/2016	10/04/2018	05/06/2017	24/04/2018	09/05/2018	10/05/2018	06/06/2018	Benchmark Met
39	17/LO/1055	228923	Elective rituximab in TTP	11/12/2017	11/04/2018	31/07/2017	11/04/2018	08/05/2018			Sponsor
40	17/EM/0355	229043	SPIRIT 2	18/08/2017	12/04/2018	10/11/2017	30/04/2018	03/05/2018	10/07/2018		Sponsor
41	17/NE/0151	223815	SGL-110 vs Treatment Choice in Adults with Previously Treated AML	24/08/2017	13/04/2018	19/07/2017	19/04/2018	20/04/2018	23/04/2018	23/04/2018	Benchmark Met
42	18/LO/0683	239811	YO40245 (IMBrave150) - Atezolizumab & Bevacizumab Vs. Sorafenib in HCC	22/01/2018	16/04/2018	13/06/2018	04/07/2018	18/07/2018	23/07/2018		Neither
43	18/EM/0015	235158	A3921145: A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA)	16/10/2017	17/04/2018	03/04/2018					Site not confirmed by Sponsor
44	16/EE/0324	203951	Prophylactic and Pre-emptive DLI for myeloid malignancies (PRO-DLI)	10/11/2017	30/04/2018	08/09/2016	30/04/2018	30/04/2018	30/04/2018	15/05/2018	Benchmark Met
45	17/EE/0368	213669	Study into the Reversal of Septic Shock with Landiolol (Beta Blockade)	16/04/2018	02/05/2018	10/11/2017	15/06/2018	21/06/2018	13/08/2018		Both

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
46	18/LO/0126	239586	Phase 1 study of WVE-210201 in patients with DMD	14/12/2017	02/05/2018	12/04/2018	31/07/2018	01/08/2018	08/08/2018	06/09/2018	Sponsor
47	18/EM/0027	235145	OPT-302 with ranibizumab for the treatment of wet AMD	15/09/2017	04/05/2018	28/02/2018	07/06/2018	07/06/2018	20/06/2018		Neither
48	17/LO/1711	234276	Synbiotic Extensively Hydrolysed Feed Study	14/02/2018	10/05/2018	24/10/2017	18/05/2018	22/05/2018			Sponsor
49	17/WS/0142	221370	PRIMUS 001	12/01/2018	01/06/2018	07/09/2017	06/07/2018	08/08/2018	05/09/2018	19/09/2018	Both
50	18/NW/0100	235042	BATCH Trial	09/03/2018	23/05/2018	13/04/2018	27/06/2018	29/06/2018	04/09/2018	05/09/2018	Sponsor
51	18/WA/0005	223997	"Best of" Radiotherapy vs "Best of" Surgery	03/04/2018	04/06/2018	12/03/2018	06/08/2018	29/08/2018			Both
52	17/WS/0147	184216	PrecisionPanc	06/02/2018	08/06/2018	05/01/2018	03/07/2018	08/08/2018	13/08/2018	20/09/2018	NHS Provider
53	17/SW/0221	232448	(CAIN457K2340) Secukinumab compared with GP2017 in Active AS	30/01/2018	20/06/2018	28/11/2017	17/09/2018	18/09/2018			Sponsor
54	18/EE/0176	236637	DELPHINUS: Daratumumab in paediatric and young adults with with ALL/LL	20/02/2018	13/08/2018	13/08/2018	15/08/2018	16/08/2018	17/08/2018		70 days not yet reached
55	18/LO/0439	240940	A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma - CA224047	14/03/2018	26/06/2018	26/06/2018	20/06/2018	27/06/2018	27/06/2018	03/07/2018	Benchmark Met
56	18/LO/0378	234232	PIONEER III	03/04/2017	28/06/2018	22/06/2018	09/12/2017	09/07/2018	20/09/2018		Sponsor
57	18/NE/0108	242365	PP-001-1001	21/08/2017	10/07/2018	08/06/2018	19/07/2018	20/07/2018	25/07/2018		Neither
58	18/YH/0223	243476	MET52	14/06/2018	16/07/2018	09/07/2018	18/07/2018	18/07/2018	24/09/2018		Sponsor
59	18/EM/0024	232898	PARC	22/01/2018	01/08/2018	03/05/2018	10/09/2018	10/09/2018	18/09/2018	23/09/2018	Benchmark Met
60	18/EM/0112	236871	ALL-RIC	26/03/2018	03/08/2018	12/06/2018	03/08/2018	11/09/2018	25/09/2018		70 days not yet reached
61	18/LO/0722	238635	A Phase 3 study of Ozanimod as induction therapy for Crohn's Disease	11/04/2018	15/08/2018	30/07/2018	28/09/2018				70 days not yet reached
62	18/WM/0190	240027	Combi-Aplus: Dabrafenib + Trametinib in BRAF+ve Melanoma	25/05/2018	15/08/2018	09/08/2018	20/08/2018	23/08/2018	30/08/2018	11/09/2018	Benchmark Met
63	18/SW/0050	235126	A3921288 Phase 3B/4 Study of Tofacitinib in Subjects with UC	02/02/2018	31/08/2018	19/04/2018	25/09/2018	26/09/2018			70 days not yet reached
64	15/LO/1904	173980	MROC: MR in Ovarian Cancer	01/06/2018	01/06/2018	09/08/2016	01/06/2018	30/07/2018			Sponsor
65	18/LO/0650	244645	PKU Low Calorie Drink Study	10/04/2018	16/07/2018	21/06/2018	16/08/2018	20/08/2018			Sponsor
66	18/SW/0121	239039	Nutrition and physical activity intervention for families with FH	15/06/2018	23/07/2018	08/06/2018	02/08/2018	02/08/2018			70 days not yet reached
67	18/NW/0476	246649	Involve-CAT	17/04/2018	06/08/2018	06/09/2018	10/09/2018	27/09/2018	27/09/2018		70 days not yet reached

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
68	18/SW/0102	233231	The effect of plasma proteins on tissue regeneration	04/06/2018	05/09/2018	13/07/2018	05/09/2018	06/09/2018	18/09/2018		70 days not yet reached
69	17/SW/0221	232448	(CAIN457K2340) Secukinumab compared with GP2017 in Active AS	30/01/2018	20/06/2018	28/11/2017					70 days not yet reached
70	18/EE/0176	236637	DELPHINUS: Daratumumab in paediatric and young adults with with ALL/LL	20/02/2018	21/06/2018						70 days not yet reached
71	18/LO/0439	240940	A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma - CA224047	14/03/2018	26/06/2018	26/06/2018	20/06/2018	27/06/2018	27/06/2018		70 days not yet reached
72	18/LO/0378	234232	PIONEER III	03/04/2017	28/06/2018	22/06/2018	09/12/2017				70 days not yet reached